Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026
Same author

Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.

JCO precision oncology·2026
Same author

Identification of a Novel <i>GOLGB1-RET</i> Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

JCO precision oncology·2026
Same author

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Nature medicine·2026
Same author

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report.

Frontiers in oncology·2026
Same author

Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer.

Journal of gastroenterology·2026

Related Experiment Video

Updated: Nov 25, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.0K

[Precision Medicine for Advanced Solid Malignancies Based on Circulating Tumor DNA Analysis].

Takahiro Ishii1, Yoshiaki Nakamura

  • 1Dept. of Gastrointestinal Oncology, National Cancer Center Hospital East.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 21, 2020
PubMed
Summary
This summary is machine-generated.

Liquid biopsy using circulating tumor DNA (ctDNA) offers a less invasive alternative to tissue analysis for cancer precision medicine. This method aids in selecting targeted therapies and monitoring treatment effectiveness.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.6K

Related Experiment Videos

Last Updated: Nov 25, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.6K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Cancer precision medicine is globally advancing, with Japan utilizing next-generation sequencing (NGS) for tumor tissue genomic profiling.
  • NGS of tumor tissue presents challenges such as extended turnaround times and limitations in capturing tumor heterogeneity and longitudinal changes.

Purpose of the Study:

  • To review the utility, drawbacks, and future potential of circulating tumor DNA (ctDNA) analysis in cancer care.
  • To highlight ctDNA as a key component of liquid biopsy for non-invasive tumor assessment.

Main Methods:

  • Review of current literature on liquid biopsy techniques, focusing on ctDNA.
  • Analysis of ctDNA's role in selecting molecularly targeted therapies.
  • Evaluation of ctDNA for monitoring therapeutic efficacy and minimal residual disease (MRD).

Main Results:

  • Liquid biopsy, particularly ctDNA analysis, provides a non-invasive method to assess tumor status using bodily fluids.
  • ctDNA analysis facilitates personalized treatment selection and monitoring of treatment response.
  • ctDNA aids in assessing recurrence risk and guiding adjuvant chemotherapy decisions through MRD detection.

Conclusions:

  • ctDNA analysis represents a significant advancement in liquid biopsy, offering a viable alternative to traditional tumor tissue analysis.
  • The application of ctDNA analysis in clinical practice is expanding, with ongoing research addressing its limitations and exploring future perspectives.